Pecaut & Co’s Novo Nordisk NVO Stock Holding History

Pecaut & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,200	Closed	-$635K	–	84
2025 Q2	$635K	Sell	9,200 -12,387	-57%	-$843K	0.21%	56
2025 Q1	$1.5M	Buy	+21,587	New	+$1.78M	0.51%	31

Other funds holding NVO

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pecaut & Co's NVO Position: Q3 2025 in Review

Pecaut & Co sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 9,200 shares — an estimated $635K sold.

Pecaut & Co first reported a position in NVO in Q1 2025 and held it in 2 quarters. The position peaked at $1.5M in Q1 2025. 1,398 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Pecaut & Co reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Pecaut & Co sold 9,200 Novo Nordisk shares in Q3 2025, an estimated $635K.
Pecaut & Co first reported a position in Novo Nordisk in Q1 2025 and held it in 2 quarters.
Pecaut & Co's Novo Nordisk position peaked at $1.5M in Q1 2025.
1,398 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Pecaut & Co's 13F filing for Q3 2025, filed 3 Nov 2025.